Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Main Inclusion Criteria: * Histopathological findings (current or previous) consistent with clinical diagnosis of DLE. * Unequivocal clinical diagnosis of 2 active DLE target lesions that were \<6 months old and amenable for clinical evaluation. This included lesions located on the scalp if they fulfilled all lesion-specific eligibility criteria. * Target lesion IGA score of at least moderate severity (≥3) at screening and baseline. * Target lesion erythema score ≥2 at screening and baseline. Main Exclusion Criteria: * Target lesion dyspigmentation score of 2 at screening or baseline. * Target lesion scarring/atrophy score of 2 at screening or baseline. * Target lesion scarring alopecia score of \>0 in scalp lesions at screening or baseline. * Medical history of systemic lupus erythematosus (SLE) with clinically significant organ involvement (American College of Rheumatology SLE classification criteria no. 6 to 9) including SLE-related pleuritis or pericarditis (by clinical evaluation and electrocardiogram), and neurologic, renal, and/or other major SLE-related organ system involvement. SLE joint involvement was acceptable. * Subjects with unstable or significant SLE disease activity findings that would, by its progressive nature and/or severity, interfere with the trial evaluation, completion, and/or procedures per the investigator's discretion. * Other skin conditions at screening or baseline that would interfere with the evaluation of DLE. * Immunosuppressive/immunomodu…